Immune-Related Adverse Events

Immunotherapy enhances a cancer patient’s immune system to fight an array of cancers. Immune checkpoint blockade can, however, induce inflammatory side effects known as immune-related Adverse Events (irAE). Because these rare but serious complications need to be quickly detected and properly treated, The Oncologist is devoting a new series designed to enhance the care of patients who may well benefit from therapeutic strategies that involve one or more these powerful immunotherapies.

This series will address the following toxicities:            
Dermatologic
Endocrine
GI and Hepatic
Heart
Neurologic
Ophthalmic
Pulmonary
Renal
Vascular

Articles

Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon
Shaheen Khan Mitchell S. von Itzstein Rong Lu Bonnie L. Bermas David R. Karp Saad A. Khan Farjana J. Fattah Jason Y. Park Jessica M. Saltarski Yvonne Gloria‐McCutchen Yang Xie Quan‐Zhen Li Edward K. Wakeland David E. Gerber
The Oncologist first published on March 13, 2020; doi: 10.1634/theoncologist.2019-0666

 

Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death‐Ligand 1 Blockade: A Case Discussion and Review of the Literature
Miruna Grecea Aurélien Marabelle Samy Ammari Christophe Massard Stéphane Champiat
The Oncologist first published on February 24, 2020; doi: 10.1634/theoncologist.2019-0671

 

Hypertrophic Lichen Planus with Histological Features of Squamous Cell Carcinoma Associated with Immune Checkpoint Blockade Therapy
Amir H. Ameri Ruth K. Foreman Priyanka Vedak Steven Chen David M. Miller Shadmehr Demehri
The Oncologist first published on February 19, 2020; doi: 10.1634/theoncologist.2019-0796

 

Commentary: Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
Leyre Zubiri, Ian M. Allen, Martin S. Taylor, Amanda C. Guidon, Steven T. Chen, Sara R. Schoenfeld, Tomas G. Neilan, Meghan E. Sise, Meghan J. Mooradian, Krista M. Rubin, Rebecca Karp Leaf, Aparna R. Parikh, Alexander Faje, Justin F. Gainor, Justine V. Cohen, Florian J. Fintelmann, Minna J. Kohler, Michael Dougan, Kerry L. Reynolds
The Oncologist first published on November 21, 2019; doi:10.1634/theoncologist.2018-0883

 

Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management
Jaydira Del Rivero, Lisa M. Cordes, Joanna Klubo‐Gwiezdzinska, Ravi A. Madan, Lynnette K. Nieman, James L. Gulley
The Oncologist first published on October 10, 2019; doi:10.1634/theoncologist.2018-0470

 

Workup and Management of Immune‐Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment
Christine Hsu, John L. Marshall, Aiwu Ruth He
The Oncologist first published on September 9, 2019; doi:10.1634/theoncologist.2018-0162

 

Workup and Management of Immune‐Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors
Bhavana Pendurthi Singh, John L. Marshall, Aiwu Ruth He
The Oncologist first published on September 6, 2019; doi:10.1634/theoncologist.2018-0304

 

Severe Epididymo‐Orchitis and Encephalitis Complicating Anti‐PD‐1 Therapy
Henry T. Quach, Charles J. Robbins, Justin M. Balko, Charles Y. Chiu, Steve Miller, Michael R. Wilson, George E. Nelson, Douglas B. Johnson
The Oncologist first published on April 1, 2019 doi:10.1634/theoncologist.2018-0722

 

Diagnosis and Management of Immune Checkpoint Inhibitor‐Associated Renal Toxicity: Illustrative Case and Review
Meghan E. Sise, Harish Seethapathy, Kerry L. Reynolds
The Oncologist first published on March 22, 2019 doi:10.1634/theoncologist.2018-0764

 

Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion
Vanessa A. Reed, Naiyer Rizvi
The Oncologist first published on March 21, 2019 doi:10.1634/theoncologist.2018-0241

 

Hematologic Complications of Immune Checkpoint Inhibitors
Elizabeth J. Davis, Joe-Elie Salem, Arissa Young, Jennifer R. Green, P. Brent Ferrell, Kristin K. Ancell, Benedicte Lebrun-Vignes, Javid J. Moslehi, Douglas B. Johnson
The Oncologist first published on February 28, 2019 doi:10.1634/theoncologist.2018-0574

 

Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature
Kerry L. Reynolds, Amanda C. Guidon
The Oncologist first published on November 27, 2018 doi:10.1634/theoncologist.2018-0359

 

 

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
Tomas G. Neilan, Mace L. Rothenberg, Laleh Amiri‐Kordestani, Ryan J. Sullivan, Richard M. Steingart, William Gregory, Subramanian Hariharan, Tarek A. Hammad, JoAnn Lindenfeld, Martin J. Murphy, Javid J. Moslehi, on behalf of the Checkpoint Inhibitor Safety Working Group
The Oncologist first published on May 25, 2018 doi:10.1634/theoncologist.2018-0157

 

Immune Checkpoint Inhibitor-Associated Myocarditis
Sarju Ganatra, Tomas G. Neilan
First Published Online on May 25, 2018 doi:10.1634/theoncologist.2018-0130

 

Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
Kerry Reynolds, Molly Thomas, Michael Dougan
The Oncologist first published on May 31, 2018 doi:10.1634/theoncologist.2018-0174